UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM SD
SPECIALIZED DISCLOSURE REPORT
STERIS plc
(Exact name of registrant as specified in its charter)
| England and Wales | 1-37614 | 98-1203539 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
Chancery House, 190 Waterside Road
Hamilton Industrial Park, Leicester LE5 1QZ
United Kingdom
(Address of principal executive offices)
J. Adam Zangerle
Registrant’s telephone number, including area code: +44 0 116 276 8636
(Name and telephone number, including area code, of the person to contact in connection with this report.)
STERIS Corporation
5960 Heisley Road, Mentor, Ohio
(Former name or former address, if changed since last report.)
Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
| x | Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2015. |
Section 1 – Conflict Minerals Disclosure
Item 1.01 Conflict Minerals Disclosure and Report
Conflict Minerals Disclosure
This Form SD of STERIS plc is filed pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1 through December 31, 2015. On November 2, 2015 STERIS Corporation (“Old STERIS”) completed a combination with Synergy Health plc, a public limited company organized under the laws of England and Wales (“Synergy”). As a result of the combination, STERIS plc became the ultimate parent company of Old STERIS (and successor issuer to Old STERIS) and Synergy. Therefore, as used in this Form SD, references to “STERIS,” “we,” “us,” or “our” refer to STERIS plc from and after November 2, 2015 and refer to Old STERIS for the period prior to November 2, 2015.
We have evaluated our current product lines and determined that certain products we manufacture or contract to manufacture contain tin, tungsten, tantalum and/or gold.
The brief description of our reasonable country of origin inquiry (“RCOI”) process, the results of our inquiry, and the determination we reached as a result of our RCOI process are included in our Conflict Minerals Report attached as an exhibit to this Form SD.
A copy of the Company’s Conflict Minerals Report is filed as Exhibit 1.01 hereto and is publicly available at: www.STERIS.com/about/ir/sec.cfm. The content of any website referred to in this Form SD is not incorporated by reference in this Form SD.
Item 1.02 Exhibit
A copy of the Company’s Conflict Minerals Report as required by Item 1.01 is filed as Exhibit 1.01 hereto.
Section 2 – Exhibits
Item 2.01 Exhibits
The following exhibit is filed as part of this report.
Exhibit 1.01 – Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
| STERIS plc | ||||||||
| By: | /s/ Kathleen L. Bardwell |
May 27, 2016 | ||||||
| Kathleen L. Bardwell Senior Vice President and Chief Compliance Officer |
||||||||
3
EXHIBIT INDEX
| Exhibit Number |
Description of Exhibit | |
| 1.01 | Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form. | |
4